anonymous
Guest
anonymous
Guest
The Better question is how in the world did they both become Executives in this diverse company. The Peter principal should have kept them as sale reps.
Darren Washington is not one of Lilly's top executives (Thank God) but at the Sr Director level he has the opportunity to negative impact the lives of many people. And that is exactly what he does.
ADG was my director and really made me feel good about the way I treated my reps. She is a motivator and full of fun energy. I really liked her and we all were successful.. ADG is da bomb.
..This also happened to me and 3 other Males when we were on that intimate team in Dallas. This woman,ADG is a wreck, that will be a VP some day with Lilly's. As a stock holder and former employee this worry the crap out of me. Bad News! Oh yes DW is also shaky as hell. THis is our new Lilly's. We will be sold because of our diversity BS.Thanks ADG. Like Trump, no matter how much propaganda you put out there you can't change the facts that you are incompetent, back stabbing, self serving who has made it where you are by climbing on all the backs of people you back stabbed and took credit for their accomplishments. Your brand and reputation is smile to the face and stab in the back while not understanding anything! Incompetent.
Diversity is Lilly and every companies future, suck it up and love it, live by it, and our lives will be better and yes I am a snow flake and love it...This also happened to me and 3 other Males when we were on that intimate team in Dallas. This woman,ADG is a wreck, that will be a VP some day with Lilly's. As a stock holder and former employee this worry the crap out of me. Bad News! Oh yes DW is also shaky as hell. THis is our new Lilly's. We will be sold because of our diversity BS.
Pete is the man.Pete Salzmann
If company is trying to save $$ they can make cuts in MHS and sales. Oncology Market managers let go and no one has noticed. Why can't there be cost saving cut on otherRAMs and Market managers? Payer decisions are made at a much higher level and local systems no longer make contracting deals. Time tmake significant cuts to RAMS and Market managers.
Now let's talk about sales. Access is extremely limited. Systems and groups are cutting off access to industry and quality interactions are minimal at best. Time to cut sales.
Bari...have been in training since January 2016 and have sold NOTHING! Brought no revenue to company and with the product being held off until 2020, this is best area to save costs. Selling Taltz to Rheums you say? Rheums are very few and on the whole, do not see reps. This is not worth the cost to retain the Bari sales force. Wake up management and do the difficult in cutting this non revenue producing leech to the company's bottom line.
Diabetes. How do you spell cluster f**k? Diabetes is using selling models from the 1990's. People, smothering customers with multitudes of reps day after day no longer works and will only result in reps continuing to be shut out of offices. Customers don't want to see three reps for Speciality and PC and everyone knows this. What's most disturbing is poor leadership on all levels. It is worrisome that DOS' don't have leadership to propose new customer strategy because they either lack leadership skills and insight to create change or they are just to damn lazy and weak to speak up and recommend change. There are way too many reps and access is very poor. If you want to save $, cutting both PC and Speciality Diabetes by 50% could easily be done and would probably be appreciated by customers.
Oncology....access is minimal at best. I dare management to track 10 reps from each area without reps knowing. I guarantee if you do this, you will quickly verify what we all know and that is Oncolgy reps do nothing and get paid on average $135,000/year plus bonus. Figure out non traditional ways to access these no-see customers and you will immediately save big $$ to the bottom line expenditures.
Alzheimer's business unit. Talk about do-nothing sales force...really? Why spend money here. If a product ever comes to market the information they have today will be updated and have to be shared at that time. Why spend $$ on an area Lilly has no product? This is a good example of poor use of investor resources and wasting $$ on a area that brings no revenue to Lilly's bottom line.
Forteo.... time of opportunity has passed and now with competitors on the market, put this dog out to pasture.
Cuts need to be made in all these areas and from a business perspective I wonder if anyone in leadership has the courage to pull the trigger and start being fiscally responsible in managing Lilly's opex.
If company is trying to save $$ they can make cuts in MHS and sales. Oncology Market managers let go and no one has noticed. Why can't there be cost saving cut on otherRAMs and Market managers? Payer decisions are made at a much higher level and local systems no longer make contracting deals. Time tmake significant cuts to RAMS and Market managers.
Now let's talk about sales. Access is extremely limited. Systems and groups are cutting off access to industry and quality interactions are minimal at best. Time to cut sales.
Bari...have been in training since January 2016 and have sold NOTHING! Brought no revenue to company and with the product being held off until 2020, this is best area to save costs. Selling Taltz to Rheums you say? Rheums are very few and on the whole, do not see reps. This is not worth the cost to retain the Bari sales force. Wake up management and do the difficult in cutting this non revenue producing leech to the company's bottom line.
Diabetes. How do you spell cluster f**k? Diabetes is using selling models from the 1990's. People, smothering customers with multitudes of reps day after day no longer works and will only result in reps continuing to be shut out of offices. Customers don't want to see three reps for Speciality and PC and everyone knows this. What's most disturbing is poor leadership on all levels. It is worrisome that DOS' don't have leadership to propose new customer strategy because they either lack leadership skills and insight to create change or they are just to damn lazy and weak to speak up and recommend change. There are way too many reps and access is very poor. If you want to save $, cutting both PC and Speciality Diabetes by 50% could easily be done and would probably be appreciated by customers.
Oncology....access is minimal at best. I dare management to track 10 reps from each area without reps knowing. I guarantee if you do this, you will quickly verify what we all know and that is Oncolgy reps do nothing and get paid on average $135,000/year plus bonus. Figure out non traditional ways to access these no-see customers and you will immediately save big $$ to the bottom line expenditures.
Alzheimer's business unit. Talk about do-nothing sales force...really? Why spend money here. If a product ever comes to market the information they have today will be updated and have to be shared at that time. Why spend $$ on an area Lilly has no product? This is a good example of poor use of investor resources and wasting $$ on a area that brings no revenue to Lilly's bottom line.
Forteo.... time of opportunity has passed and now with competitors on the market, put this dog out to pasture.
Cuts need to be made in all these areas and from a business perspective I wonder if anyone in leadership has the courage to pull the trigger and start being fiscally responsible in managing Lilly's opex.
I am a Lilly Oncology rep. I have good access to oncologists and I make a difference in their prescribing habits, so don't paint us all with a broad brush. Some reps just suck and can't develop relationships with smart/discerning physicians. Stop whining about reps who have great relationships (and make a difference) making more money than you. Sometimes you just have to look in the mirror to find who to blame.
Ladies and gentlemen, this is the epitome of Fake News.I am a Lilly Oncology rep. I have good access to oncologists and I make a difference in their prescribing habits, so don't paint us all with a broad brush. Some reps just suck and can't develop relationships with smart/discerning physicians. Stop whining about reps who have great relationships (and make a difference) making more money than you. Sometimes you just have to look in the mirror to find who to blame.
Diversity wowDiversity is Lilly and every companies future, suck it up and love it, live by it, and our lives will be better and yes I am a snow flake and love it.
I am a Lilly Oncology rep. I have good access to oncologists and I make a difference in their prescribing habits, so don't paint us all with a broad brush. Some reps just suck and can't develop relationships with smart/discerning physicians. Stop whining about reps who have great relationships (and make a difference) making more money than you. Sometimes you just have to look in the mirror to find who to blame.